Literature DB >> 25584927

Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.

Marenza Leo1, Francesca Menconi, Roberto Rocchi, Francesco Latrofa, Eleonora Sisti, Maria Antonietta Profilo, Barbara Mazzi, Eleonora Albano, Marco Nardi, Paolo Vitti, Claudio Marcocci, Michele Marinò.   

Abstract

BACKGROUND: Clinically overt Graves' orbitopathy (GO) is associated with Graves' disease (GD) in approximately 95% of cases, whereas the remaining 5% is observed in patients with hypothyroid autoimmune thyroiditis (AT) or without overt thyroid dysfunction (euthyroid GO). However, it is not known whether there is a difference in terms of GO phenotype between patients with GD and those with hypothyroid AT or without thyroid dysfunction, and hence this is investigated here.
METHODS: The study design was to evaluate retrospectively all consecutive patients with a recent manifestation of GO, seen at their first visit to a tertiary referral center over a period of 10 years. In total, 358 GO patients were studied, and all of them underwent GO assessment.
RESULTS: Of the 358 patients studied, 341 had hyperthyroid GD, 10 had AT with hypothyroidism, and seven had euthyroid GO. Age, sex, and smoking habits were similar in the three groups, as was the time since GO was first noticed (GO duration). The vast majority of patients had moderate to severe, active GO, as expected in a tertiary referral center. Exophthalmometry, eyelid width, clinical activity score (CAS), diplopia, and visual acuity did not differ between patients with GD and those with AT or euthyroid GO, suggesting that the GO phenotype was similar. Accordingly, the NOSPECS score did not differ between the three groups.
CONCLUSIONS: The phenotype of GO is similar regardless of the underlying thyroid disease. Because this study was performed in a tertiary referral center, this conclusion can be restricted only to patients who develop moderate to severe GO.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25584927     DOI: 10.1089/thy.2014.0475

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves' orbitopathy.

Authors:  Giovanna Rotondo Dottore; Riccardo Chiarini; Maria De Gregorio; Marenza Leo; Giamberto Casini; Luca Cestari; Stefano Sellari-Franceschini; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Endocrine       Date:  2017-01-17       Impact factor: 3.633

Review 2.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

3.  A genome-wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves' orbitopathy.

Authors:  Z Xin; L Hua; T-T Shi; X Tuo; F-Y Yang; Y Li; X Cao; J-K Yang
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

4.  Thyroid Association Ophthalmopathy in Hashimoto's Thyroiditis: a Case Report.

Authors:  Deepak Jain; Sudhir Mor; Hari Krishan Aggarwal; Pulkit Chhabra; Promil Jain
Journal:  Maedica (Bucur)       Date:  2017-01

5.  Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO).

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-12-18       Impact factor: 4.256

6.  Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-06-27       Impact factor: 4.256

7.  Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Authors:  M Leo; E Sabini; I Ionni; A Sframeli; B Mazzi; F Menconi; E Molinaro; F Bianchi; F Brozzi; P Santini; R Elisei; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-08-30       Impact factor: 4.256

8.  Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.

Authors:  Giovanna Rotondo Dottore; Liborio Torregrossa; Patrizio Caturegli; Ilaria Ionni; Angela Sframeli; Elena Sabini; Francesca Menconi; Paolo Piaggi; Stefano Sellari-Franceschini; Marco Nardi; Francesco Latrofa; Paolo Vitti; Claudio Marcocci; Fulvio Basolo; Michele Marinò
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389

9.  A Case of Unilateral Dermopathy Possibly Related to Graves' Disease.

Authors:  Cosimo Rodia; Francesca Menconi; Laura Mazoni; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2019-06-11

10.  Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.

Authors:  Elena Sabini; Ilaria Ionni; Roberto Rocchi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.